Sangamo Inks Definitive $211M Asset Sale to PTC for Fabry Gene Therapy
SGMOQ has more than doubled off its 52-week low of $0.03.
Summary
Sangamo signed a definitive agreement to sell its ST-920 Fabry disease gene therapy assets to PTC Therapeutics for $111 million cash plus up to $100 million in milestones, pending bankruptcy court approval on September 10.
Key Events · M&A and Partnerships · SGMOQ
-
Definitive APA Signed with PTC
On August 25, 2026, an Asset Purchase Agreement was executed, selling all ST-920 (isaralgagene civaparvovec) Fabry disease assets to PTC Therapeutics.
-
$111M Cash at Closing
PTC will pay $111 million in cash at closing, subject to bankruptcy court approval and HSR clearance.
-
Up to $100M in Milestones
Contingent payments include $80 million upon FDA accelerated approval and $20 million upon full approval of the ST-920 BLA based on the STAAR studies.
-
Bankruptcy Court Hearing Sept 10
A sale approval hearing is scheduled for September 10, 2026; closing must occur by the October 15, 2026 End Date.
Analysis · SGMOQ · Life Sciences
A definitive asset purchase agreement with PTC Therapeutics for its ST-920 Fabry disease gene therapy program has been executed by Sangamo. The deal brings $111 million in cash at closing plus up to $100 million in FDA milestone payments — capital that will fund the Chapter 11 estate's wind-down and creditor recoveries. Formalizing the winning bid announced August 13, the agreement adds exact consideration terms and a September 10 bankruptcy court approval hearing. For a company trading at $0.16 with a $66 million market cap, the $111 million closing payment alone exceeds the entire equity value, though proceeds flow to creditors rather than shareholders in the bankruptcy process.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1753 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGMOQ was trading at $0.16 on OTC in the Life Sciences sector, with a market capitalization of approximately $66.5M. The 52-week trading range was $0.03 to $0.77. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.